Stratμm™ offers controlled and pulse release options in an injectable form
Controlled Release
Stratμm™ technology titrates drug release kinetics to enable novel injectable drug delivery products. We create uniform, monodisperse microspheres using our technology. Our depots allow for discrete control over release rate, including linear kinetics, offering sustained release for any desired length of time.
This application is particularly useful for pharmaceuticals for which compliance is critical, such as contraception, antipsychotic, addiction and bacterial resistance medications.
Pulse Release
The Stratμm™ technology revolutionizes injectable pharmaceuticals with delayed release of active pharmaceutical ingredients for true pulse release. We tuned the composition of the shell to release the active after 30 days.
Stratμm™ is particularly useful to improve patient compliance by reducing the number of injections (i.e. vaccines or ocular therapies). It also enables previously unattainable dosing regimens and pharmacokinetics.
Stratμm™ microparticles open up a whole new world of possibilities
- Particle sizes down to 10 μm with ± 5% deviation from the mean diameter
- Uses a water “carrier” stream
- Analogous to emulsion processes
- Requires lyophilization
- Compatible with PLGAs, PLAs, PCLs, PCPHs, alginates, gelatins, and other biopolymers
- Good for injectable small molecules, proteins, peptides, vaccines, and heat-labile molecules
Speak With An Expert
Nathan Dormer
Director, Drug Product Development
Nathan Dormer, Ph.D., is the Director of Drug Product Development at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s Lenexa, KS site where he supports a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.
